Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER [electronic resource]
Producer: 20180430Description: 4793-4804 p. digitalISSN:- 1557-3265
- Animals
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Breast Neoplasms -- drug therapy
- Cell Line, Tumor
- Everolimus -- administration & dosage
- Female
- Humans
- MCF-7 Cells
- Mice, Inbred BALB C
- Mice, Nude
- Piperazines -- administration & dosage
- Pyridines -- administration & dosage
- Receptors, Estrogen -- genetics
- Selective Estrogen Receptor Modulators -- administration & dosage
- Tetrahydronaphthalenes -- administration & dosage
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.